Built by people who built the ADC field.
ImmuVia's team includes inventors of FDA-approved antibody therapeutics — Kadcyla®, Elahere™, and Sarclisa® — and decades of experience taking targeted oncology biologics from discovery to the clinic.
Leadership
A serial entrepreneur with a track record of founding companies in biologics (oncology) and medical devices, with a background in asset management and M&A strategy. He has published peer-reviewed research in immunology and computational systems biology.
Thirty-plus years in targeted cancer therapeutics, antibody technologies, and the biology of apoptosis. He played a pivotal role in the discovery of three FDA-approved anti-cancer biologics — Kadcyla®, Elahere™, and Sarclisa® — and is an inventor on 28 issued US patents with more than 100 publications.
More than 30 years across the discovery and development of targeted biologics, including the technology transfer and scale-up synthesis that supported clinical trials of the FDA-approved ADCs Kadcyla® and Elahere™. Inventor on over 100 issued US patents.
Twenty-plus years in targeted cancer therapies, directing IND-enabling studies and next-generation ADC programs. She led the discovery and development of pivekimab sunirine from inception to IND submission.
A physician-scientist and internationally recognized expert in stem cell transplantation for hematologic malignancies, with a career leading clinical trials at leading cancer centers.
More than 20 years founding biotechnology companies and developing pharmaceuticals, with three exits totaling over $1B and $200M+ raised. Programs he developed include Pegcystianine™ (FDA breakthrough designation), Adlarity™, and Azstaris™.
Scientific & clinical advisors
Thirty-plus years leading ADC discovery and development, with scientific contributions to Kadcyla® and Elahere™ and more than 120 peer-reviewed publications.
A leading oncologist who helped establish the efficacy of BRAF, MEK, and combined BRAF/MEK inhibition, including work on Zelboraf®. Co-founder of Scorpion Therapeutics and author of more than 300 peer-reviewed publications.
Forty-plus years as a hematologist-oncologist in the experimental therapeutics of antineoplastic agents and clinical trials across hematologic malignancies and solid tumors.
Forty-plus years in the regulatory affairs, development, and manufacturing of biopharmaceuticals, supporting regulatory filings from Phase 1 through commercialization.
Phase 1 principal investigator
Dr. Von Hoff will serve as Principal Investigator for the IMV-M™ Phase 1 trial — the investigator behind the approvals of gemcitabine, nab-paclitaxel, and nanoliposomal irinotecan, and one of the most experienced early-phase oncology trialists in the field. His laboratory independently replicated IMV-M™'s anti-tumor efficacy in a foundation-funded study at TGen.